Beta Bionics vs Doximity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beta Bionics (Nasdaq: BBNX) makes the iLet Bionic Pancreas, the first autonomous closed-loop insulin delivery system; reported Q1 2026 revenue of $27.6M (+57% YoY) with 24,000+ active users.
About
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
About
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Beta Bionics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.